SynthesisFrontiers in medicine2022
The Outcomes of XEN Gel Stent Implantation: A Systematic Review and Meta-Analysis.
Synthesis in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Minimally Invasive Glaucoma Surgery.Deutsches Arzteblatt international · 2025Pooled it
- Minimally Invasive Bleb Surgery for Glaucoma: A Health Technology Assessment.Ontario health technology assessment series · 2024Pooled it
- Effectiveness and safety of the XEN45 gel stent compared to trabeculectomy in primary open-angle glaucoma: the Gold-Standard Pathway Study.BMJ open ophthalmology · 2025Trial
- Enabling adaptability and hydraulic resistance in minimally invasive glaucoma surgery using an architecture-driven approach.iScience · 2026Article
- Update on XEN Gel Stent: A Narrative Review on Indications, Surgical Technique, and Postoperative Management.Ophthalmology and therapy · 2026Review
- XEN‑45 implantation for refractory secondary glaucoma.BMC ophthalmology · 2025Article
- Surgical Outcomes of XEN45 Gel Stent Using Ab Interno Technique in Open-Angle Glaucoma: A 2-Year Follow-Up Study.Journal of clinical medicine · 2025Article
- Should We Fear Wipe-Out in Glaucoma Surgery?Diagnostics (Basel, Switzerland) · 2025Review
- Preserflo MicroShunt Implantation: A Narrative Review of Its Standalone Benefits vs. Combined Use with Phacoemulsification in Managing Open-Angle Glaucoma.Ophthalmology and therapy · 2025Review
- Ab-Externo XEN Gel stent implantation effectively treated refractory glaucoma with prior failed shunt tube.BMC ophthalmology · 2024Article
- Long-term effectiveness and safety of XEN45 in open-angle glaucoma patients.International ophthalmology · 2024Article
- Complications Following XEN45 Gel Stent and Glaucoma Drainage Device Implantation During Glaucoma Fellowship.Cureus · 2024Article
- Swiss Multicenter Ab Interno XEN45 Gel Stent Study: 2-Year Real-World Data.Ophthalmology and therapy · 2024Article
- Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma.Scientific reports · 2024Article
- Recanalization of Xen45 gel stent implant occlusion using 10 - 0 nylon suture in refractory glaucoma: a case report.BMC ophthalmology · 2023Article
- New Devices in Glaucoma.Ophthalmology and therapy · 2023Review
- Effectiveness and Safety of Xen Gel Stent in Glaucoma Surgery: A Systematic Review of the Literature.Journal of clinical medicine · 2023Review
- Effectiveness of Microinvasive Glaucoma Surgery in the United States: Intelligent Research in Sight Registry Analysis 2013-2019.Ophthalmology · 2023Article
- Long-Term Effectiveness of XEN 45 Gel-Stent in Open-Angle Glaucoma Patients.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Four-Year Outcome of XEN 45 Gel Stent Implantation in a Swedish Population.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeXEN gel stents are used for the treatment of open-angle glaucoma (OAG), including primary and secondary glaucoma that are uncontrolled by previous medical therapy and cases with previous failed surgery. Our aim was to systematically review of the clinical data of currently published ab-interno XEN gel stents with an emphasis on intraocular pressure (IOP), antiglaucoma medication outcomes, and safety profiles.
methodsWe analyzed all of the publications (MEDLINE, EMBASE, Cochrane Library) on the ab-interno XEN gel stent to evaluate the reduction in IOP and antiglaucoma medications following the procedure. The primary outcomes measured for the meta-analysis were reduction in IOP and anti-glaucoma medications. The secondary outcome were adverse events. For each study, we used a random effects analysis model to calculate the mean difference and 95% confidence intervals for the continuous results (reduction in IOP and antiglaucoma medications) using the inverse variance statistical method.
resultsFive hundred twenty-seven articles were checked and 56 studies were found to be relevant with a total of 4,410 eyes. There was a significant reduction in IOP as well as in the number of medications required in patients treated with ab-interno XEN implant either alone or combined with cataract surgery. This new treatment for various types of glaucoma reduced the IOP by 35% to a final average close to 15 mmHg. This reduction was accompanied by a decrease in the number of antiglaucoma medications in all the studies, approximately 2 classes of medication at the price of more needlings. The overall complete success rate was 21.0-70.8% after 2 years using strict criteria originally designed to record success rate in filtration surgery. The incidence of complications vision-threatening was low at <1%.
conclusionsXEN gel stent was effective and safe for primary and secondary OAG. Further studies should be performed to investigate the impact of ethnicity on the success and failure rate after XEN implantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.